Affordable Access

deepdyve-link
Publisher Website

Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis.

Authors
  • Lingaratnam, Senthil M
  • Slavin, Monica A
  • Thursky, Karin A
  • Teh, Benjamin W
  • Haeusler, Gabrielle M
  • Seymour, John F
  • Rischin, Danny
  • Worth, Leon J
Type
Published Article
Journal
Leukemia & Lymphoma
Publisher
Informa UK (Taylor & Francis)
Publication Date
Jan 01, 2015
Volume
56
Issue
1
Pages
157–162
Identifiers
DOI: 10.3109/10428194.2014.911861
PMID: 24717111
Source
Medline
Keywords
License
Unknown

Abstract

Pneumocystis jirovecii pneumonia (PJP) is seen increasingly in non-human immunodeficiency virus (HIV) infected immunocompromised populations, but few cases have previously been reported in association with gemcitabine therapy. We identified all patients administered gemcitabine between March 2009 and December 2012 at the Peter MacCallum Cancer Centre. Cases of PJP were identified using accepted definitions. Overall, 288 gemcitabine-treated patients were identified. Nine cases of PJP were detected, corresponding to an overall rate of 3.1% (95% confidence interval [CI] 1.5-5.7%). PJP was diagnosed during gemcitabine therapy in seven patients, a median of 67 (range 31-109) days from commencement. Among patients with lymphoma, 4/22 developed PJP, corresponding to a rate of 18.2% (95% CI 6.1-38.2%). Fewer infections were associated with breast, lung and gastrointestinal malignancies (1/24 [4.2%], 3/118 [2.5%] and 1/61 [1.6%], respectively). A risk-based tool incorporating concomitant steroid therapy can be applied to target high-risk populations who would benefit from PJP prophylaxis during gemcitabine therapy.

Report this publication

Statistics

Seen <100 times